Literature DB >> 22339487

Synthesis, structural characterization, solution behavior, and in vitro antiproliferative properties of a series of gold complexes with 2-(2'-pyridyl)benzimidazole as ligand: comparisons of gold(III) versus gold(I) and mononuclear versus binuclear derivatives.

Maria Serratrice1, Maria A Cinellu, Laura Maiore, Maria Pilo, Antonio Zucca, Chiara Gabbiani, Annalisa Guerri, Ida Landini, Stefania Nobili, Enrico Mini, Luigi Messori.   

Abstract

A variety of gold(III) and gold(I) derivatives of 2-(2'-pyridyl)benzimidazole (pbiH) were synthesized and fully characterized and their antiproliferative properties evaluated in a representative ovarian cancer cell line. The complexes include the mononuclear species [(pbi)AuX(2)] (X = Cl, 1; OAc, 2), [(pbiH)AuCl] (3), [(pbiH)Au(PPh(3))][PF(6)] (4-PF(6)), and [(pbi)Au(L)] (L = PPh(3), 5; TPA, 6), and the binuclear gold(I)/gold(I) and gold(I)/gold(III) derivatives [(PPh(3))(2)Au(2)(μ(2)-pbi)][PF(6)] (10-PF(6)), [ClAu(μ(3)-pbi)AuCl(2)] (7),and [(PPh(3))Au(μ(3)-pbi)AuX(2)][PF(6)] (X = Cl, 8-PF(6); OAc, 9-PF(6)). The molecular structures of 6, 7, and 10-PF(6) were determined by X-ray diffraction analysis. The chemical behavior of these compounds in solution was analyzed both by cyclic voltammetry in DMF and absorption UV-vis spectroscopy in an aqueous buffer. Overall, the stability of these gold compounds was found to be acceptable for the cellular studies. For all complexes, relevant antiproliferative activities in vitro were documented against A2780 human ovarian carcinoma cells, either resistant or sensitive to cisplatin, with IC(50) values falling in the low micromolar or even in the nanomolar range. The investigated gold compounds were found to overcome resistance to cisplatin to a large degree. Results are interpreted and discussed in the frame of current knowledge on cytotoxic and antitumor gold compounds.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22339487     DOI: 10.1021/ic202639t

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  7 in total

1.  Inhibition Mechanism of Urease by Au(III) Compounds Unveiled by X-ray Diffraction Analysis.

Authors:  Luca Mazzei; Margot N Wenzel; Michele Cianci; Marta Palombo; Angela Casini; Stefano Ciurli
Journal:  ACS Med Chem Lett       Date:  2019-01-04       Impact factor: 4.345

2.  DNA interaction, anticancer, cytotoxicity and genotoxicity studies with potential pyrazine-bipyrazole dinuclear µ-oxo bridged Au(III) complexes.

Authors:  Darshana N Kanthecha; Bhupesh S Bhatt; Mohan N Patel; Foram U Vaidya; Chandramani Pathak
Journal:  Mol Divers       Date:  2021-09-24       Impact factor: 3.364

3.  Gold(I) complexes of 9-deazahypoxanthine as selective antitumor and anti-inflammatory agents.

Authors:  Ján Vančo; Jana Gáliková; Jan Hošek; Zdeněk Dvořák; Lenka Paráková; Zdeněk Trávníček
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

4.  Combined Effect of Caspase-Dependent and Caspase-Independent Apoptosis in the Anticancer Activity of Gold Complexes with Phosphine and Benzimidazole Derivatives.

Authors:  Lara Rouco; Ángeles Sánchez-González; Rebeca Alvariño; Amparo Alfonso; Ezequiel M Vázquez-López; Emilia García-Martínez; Marcelino Maneiro
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-24

5.  Anticancer gold(iii)-bisphosphine complex alters the mitochondrial electron transport chain to induce in vivo tumor inhibition.

Authors:  Jong Hyun Kim; Samuel Ofori; Sean Parkin; Hemendra Vekaria; Patrick G Sullivan; Samuel G Awuah
Journal:  Chem Sci       Date:  2021-04-29       Impact factor: 9.825

Review 6.  Gold-Based Medicine: A Paradigm Shift in Anti-Cancer Therapy?

Authors:  Chien Ing Yeo; Kah Kooi Ooi; Edward R T Tiekink
Journal:  Molecules       Date:  2018-06-11       Impact factor: 4.411

7.  Comparing the Antileishmanial Activity of Gold(I) and Gold(III) Compounds in L. amazonensis and L. braziliensis in Vitro.

Authors:  Karen Minori; Letícia B Rosa; Riccardo Bonsignore; Angela Casini; Danilo C Miguel
Journal:  ChemMedChem       Date:  2020-09-28       Impact factor: 3.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.